Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis

BMC Urology

Table 1 Basic characteristics of the studies included in the current meta-analysis

					Methylation %		Number		Gender		Grade		Stage		Tumor number
First author	Year	Ethnicity	Method	Sample	Case	Control	Cases	Controls	Male	Female	3	1-2	≥2	≤1	Multiple	Single
Maruyama et al.	2001	Caucasians	MSP	Tissue	29.9 %	-	97	-	-	-	65	32	-	-	-	-
Meng et al.	2007	Asians	MSP	Urine	15.2 %	0 %	92	30	-	-	-	-	27	65	-	-
Yu et al.	2007	Asians	MSP	Urine	16.7 %	0 %	132	30	-	-	-	-	-	-	-	-
Cabello et al.	2011	Caucasians	*	Urine	27.1 %	6 %	96	50	-	-	36	60	18	78	-	-
Agundez et al.	2011	Caucasians	*	Tissue	62.6 %	0 %	91	10	82	9	-	-	-	-	44	47
Lin et al.	2011	Asians	MSP	Serum	30.7 %	0 %	127	41	88	39	31	96	49	78	74	53
Lin et al.	2012	Asians	MSP	Tissue	35.3 %	0 %	133	43	94	39	37	96	48	85	82	51
Lin et al.	2013	Asians	MSP	Tissue	60.6 %	0 %	71	23	49	22	-	-	32	39	43	28
Lin et al.	2014	Asians	MSP	Tissue	44.9 %	0 %	178	38	124	54	-	-	-	-	76	102

MSP methylation-specific polymerase chain reaction, “-” indicates data not available
*indicates MS-MLPA (Methylation-Specific Multiplex Ligation-Dependent Probe Amplification)

ISSN: 1471-2490